

Curriculum Vitae; Per thor Straten

CURRICULUM VITAE; Per thor Straten

Date of birth: April 25th, 1957

Place of birth: Copenhagen, Denmark

Nationality: Danish

Education and degrees:

April 2009 Professor, University of Copenhagen

September 1998 Ph.D., The Open University, Milton Keynes, United Kingdom (Thesis: T-cell response against melanoma)

December 1992 M.Sc. (Molecular biology), University of Copenhagen. (Thesis: Analysis of T-cell receptor variable region usage in tumor infiltrating lymphocytes (TIL) in malignant melanoma)

March 1991 B.S. in Biology, University of Copenhagen.

Employment:

October 2006 Director, Centre for Cancer Immunotherapy (CCIT), Dept. of Hematology, University Hospital Herlev, Denmark

August 2001 Group Head, Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49 DK-2100 Copenhagen Ø

January 1998 Senior Scientist, Dept. of Cell Biology and Cancer, Danish Cancer Society, Denmark

January 1992 Scientific Assistant, Dept. of Cell Biology and Cancer, Danish Cancer Society, Denmark

Industry

2003 – 2005 Founder and board member of Survac ApS and CAVAC Aps. Co-author of five patents on peptide antigens recognized by CTL.

Teaching/reviewing

Tutorial lectures on tumor immunology at universities and the industry. Supervisor for numerous Master and Phd-students in the group and externally. Reviewer for a long list of high-ranking international scientific journals.

Publications:

Author/co-author of more than 130 articles and patents in the area of tumor immunology and immunotherapy

Miscellaneous:

Founding member of European Society for Cancer Immunology and Immunotherapy (ESCI), and founding member of Copenhagen Cluster of Immunology and "Graduate school of immunology", Founding member of Nordic centre for development of anti-tumor vaccine concepts (NCEV), co-organizer of Danish Cancer Society annual symposia 2005, Grant reviewer for Dutch Cancer Society, Cancerföreningen i Stockholm/Konung Gustaf V's Jubileumsfond, , reviewer for several journals in tumor immunology, Member of FP6 EU projects ESTDAB and OISTER. Member of World Immunotherapy Council, Steering committee member for PIVAC (progress in vaccination against cancer), main organizer of conference on "Progress in Vaccination against Cancer" 11 (PIVAC11) held in Copenhagen fall 2011, Editorial Board Member for Cancer Immunology and Immunotherapy (CII).

Curriculum Vitae; Per thor Straten

List of publications; short version

113. Hofmann,U.B., Voigt,H., Andersen,M.H., thor Straten,P., Becker,J.C., and Eggert,A.O. (2009). Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes. *Eur. J. Immunol.* *39*, 1419-1424.
114. Sorensen,R.B., Berge-Hansen,L., Junker,N., Hansen,C.A., Hadrup,S.R., Schumacher,T.N., Svane,I.M., Becker,J.C., thor Straten,P., and Andersen,M.H. (2009). The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. *PLoS. ONE.* *4*, e6910.
115. thor Straten,P. and Becker,J.C. (2009). Adoptive cell transfer in the treatment of metastatic melanoma. *J. Invest Dermatol.* *129*, 2743-2745.
116. Berntsen,A., Brimnes,M.K., thor Straten,P., and Svane,I.M. (2010). Increase of Circulating CD4+CD25highFoxp3+ Regulatory T Cells in Patients With Metastatic Renal Cell Carcinoma During Treatment With Dendritic Cell Vaccination and Low-Dose Interleukin-2. *J. Immunother.* *31*, 771-780.
117. Sondergaard,H., Galsgaard,E.D., Bartholomaeussen,M., thor Straten,P., Odum,N., and Skak,K. (2010). Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes. *J. Immunother.* *33*, 236-249.
118. Andersen,M.H., Junker,N., Ellebaek,E., Svane,I.M., and thor Straten,P. (2010). Therapeutic cancer vaccines in combination with conventional therapy. *J. Biomed. Biotechnol.* *2010*, 237623.
119. Trepiaakas,R., Berntsen,A., Hadrup,S.R., Bjorn,J., Geertsen,P.F., thor Straten,P., Andersen,M.H., Pedersen,A.E., Soleimani,A., Lorentzen,T., Johansen,J.S., and Svane,I.M. (2010). Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. *Cytotherapy.* *2*, 721-734.
120. Sorensen,R.B., Hadrup,S.R., Svane,I.M., Hjortso,M.C., thor Straten,P., and Andersen,M.H. (2011). Indoleamine 2,3-dioxygenase specific cytotoxic T cells as immune regulators. *Blood* *117*, 2200-2210.
121. Sorensen,R.B., Kollgaard,T., Andersen,R.S., van der Berg,J., Svane,I.M., thor Straten,P., and Andersen,M.H. (2011). Spontaneous cytotoxic T-cell reactivity against indoleamine 2-dioxygenase-2. *Cancer Res.* *2011 Mar 15*;71(6):2038-44.
122. Bjoern,J., Brimnes,M.K., Andersen,M.H., thor Straten,P., and Svane,I.M. (2011). Changes in peripheral blood level of regulatory T cells in malignant melanoma patients during treatment with dendritic cell vaccination and low dose IL-2. *Scand. J. Immunol.* *73*, 222-233.
123. thor Straten,P. and Andersen,M.H. (2011). The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. *Oncotarget.* *1*, 239-245.
124. Junker,N., Andersen,M.H., Wenandy,L., Dombernowsky,S.L., Kiss,K., Sorensen,C.H., Therkildsen,M.H., Von,B.C., Andersen,E., thor Straten,P., and Svane,I.M. (2011). Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. *Cytotherapy.*